Literature DB >> 24152946

The impact of perioperative blood glucose levels on pancreatic cancer prognosis and surgical outcomes: an evidence-based review.

Siddharth R Raghavan1, Umashankar K Ballehaninna, Ronald S Chamberlain.   

Abstract

Although diabetes mellitus (DM) and pancreatic cancer (PC) are intricately linked, a comprehensive review addressing the impact of DM on PC prognosis and surgical outcomes is lacking. PubMed search was performed (1980-2012) using keywords "pancreatic cancer", "diabetes mellitus", "glucose intolerance", "pancreatic resection", "prognosis", and "post-operative outcomes". The search results were analyzed to determine the strength of association between DM and PC and to assess the impact of DM on PC prognosis and postoperative outcomes. Thirty-one studies involving 38,777 patients were identified. Patients with non-insulin-dependent DM have 1.5-2 fold increased relative risk of developing PC. Non-insulin-dependent DM is identified in 25.7% of patients with PC compared to 10.4% age-matched controls (95% confidence interval, 1.5-4.7; P < 0.0001). Patients with PC are more likely to have a diagnosis of new-onset DM than age-matched controls (14.7% vs 2.7%; P < 0.0001). Patients with PC with DM have a significantly lower overall survival than those without DM (14.4 vs 21.7 months; P < 0.001). The presence of DM significantly increases overall postoperative complication rates (45.6% vs 35.6%; P < 0.008). Patients with new-onset non-insulin-dependent DM are at a higher risk of developing PC and have a worse long-term survival and a higher rate of postoperative complications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24152946     DOI: 10.1097/MPA.0b013e3182a6db8e

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  19 in total

Review 1.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

2.  Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer.

Authors:  Sara H Olson; Youming Xu; Keri Herzog; Amethyst Saldia; Ersilia M DeFilippis; Peter Li; Peter J Allen; Eileen M O'Reilly; Robert C Kurtz
Journal:  Pancreas       Date:  2016-08       Impact factor: 3.327

3.  Diabetes mellitus and pancreatic cancer: why the association matters?

Authors:  Phil A Hart; Suresh T Chari
Journal:  Pancreas       Date:  2013-11       Impact factor: 3.327

4.  Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer.

Authors:  Yueming Zhang; Yaolin Xu; Dansong Wang; Tiantao Kuang; Wenchuan Wu; Xuefeng Xu; Dayong Jin; Wenhui Lou
Journal:  Int J Clin Oncol       Date:  2020-09-21       Impact factor: 3.402

5.  Nomogram and a predictive model for postoperative hemorrhage in preoperative patients of laparoscopic pancreaticoduodectomy.

Authors:  Dongrui Li; Chengxu Du; Jiansheng Zhang; Zhongqiang Xing; Jianhua Liu
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

6.  Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study.

Authors:  Gianpaolo Balzano; Erica Dugnani; Alessandra Gandolfi; Marina Scavini; Valentina Pasquale; Francesca Aleotti; Daniela Liberati; Gaetano Di Terlizzi; Giovanna Petrella; Michele Reni; Claudio Doglioni; Emanuele Bosi; Massimo Falconi; Lorenzo Piemonti
Journal:  PLoS One       Date:  2016-11-04       Impact factor: 3.240

7.  Increased serum levels of betatrophin in pancreatic cancer-associated diabetes.

Authors:  Hendra Susanto; Ta-Yu Liu; Chang-Chiang Chen; Jerry D T Purnomo; Shu-Fan Chen; Chih-Hong Wang
Journal:  Oncotarget       Date:  2016-07-05

8.  Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: association with E-cadherin1 (CDH1) promoter methylation.

Authors:  Takeshi Saito; Hiroki Mizukami; Satoko Umetsu; Chiaki Uchida; Wataru Inaba; Makoto Abe; Kazuhisa Takahashi; Kazuhiro Kudo; Chieko Itabashi; Soroku Yagihashi; Kenichi Hakamada
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

9.  Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma.

Authors:  Brandon C Chapman; Ana Gleisner; Devin Rigg; Wells Messersmith; Alessandro Paniccia; Cheryl Meguid; Csaba Gajdos; Martin D McCarter; Richard D Schulick; Barish H Edil
Journal:  JOP       Date:  2018-03-30

10.  Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis.

Authors:  Hui Shen; Ming Zhan; Wei Wang; Dong Yang; Jian Wang
Journal:  Onco Targets Ther       Date:  2016-03-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.